Fig. 4

FGF2 lead to opposite effects on cell cycle in FGFR1 amplified and non-amplified ER + cells. A-D. The proportion of cells in each phase of the cell cycle was evaluated through PI staining-based flow cytometry analysis in FGFR1 amplified cell lines CAMA1 and MDA-MB-134 (A and B) and non-amplified cell lines MCF7 and T47D (C and D). The cells were collected from 2D cultures after being exposed to FGF2 (25ng/ml) with or without TAS-120 (1.0 µM) for 24 hours. The symbol “#’ indicates that the G1 phase in FGF2-treated cells is significantly higher compared to DMSO-treated cells (p < 0.05). The symbol “*’ shows that the G1 phase in FGF2 plus TAS-120 treated cells is significantly lower compared to FGF2-treated cells (p < 0.05). E-G. TCGA ER + breast cancer patients data analysis for interactions in the generalized linear model between FGF2 (X-axes):FGFR1 expression and their impact on GSEA pathways related to M phase (C), G2/M checkpoints (F) and S phase (G) (Y-axes, n = 601). The three linear fit curves and 95% C.I. (grey shaded area) are shown to indicate the interaction effects between FGF2 and FGFR1 expression, where FGFR1 expression levels were grouped by tertiles (high n = 206; low n = 199; med n = 196)